Ryzneuta® (efbemalenograstim alfa-vuxw) – New drug approval
November 16, 2023 - The FDA approved Evive Biotechnology’s Ryzneuta (efbemalenograstim alfa-vuxw), to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Top